NCCN Guidelines® Insights: Survivorship, Version 2.2024

Featured Updates to the NCCN Guidelines

Authors:
Tara Sanft Yale Cancer Center/Smilow Cancer Hospital

Search for other papers by Tara Sanft in
Current site
Google Scholar
PubMed Close
 MD
,
Andrew T. Day UT Southwestern Simmons Comprehensive Cancer Center

Search for other papers by Andrew T. Day in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Mindy Goldman UCSF Helen Diller Family Comprehensive Cancer Center

Search for other papers by Mindy Goldman in
Current site
Google Scholar
PubMed Close
 MD
,
Shannon Ansbaugh Patient Advocate

Search for other papers by Shannon Ansbaugh in
Current site
Google Scholar
PubMed Close
,
Saro Armenian City of Hope National Medical Center

Search for other papers by Saro Armenian in
Current site
Google Scholar
PubMed Close
 DO, MPH
,
K. Scott Baker Fred Hutchinson Cancer Center

Search for other papers by K. Scott Baker in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Tarah J. Ballinger Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Search for other papers by Tarah J. Ballinger in
Current site
Google Scholar
PubMed Close
 MD
,
Wendy Demark-Wahnefried O’Neal Comprehensive Cancer Center at UAB

Search for other papers by Wendy Demark-Wahnefried in
Current site
Google Scholar
PubMed Close
 PhD, RD
,
Nathan Paul Fairman UC Davis Comprehensive Cancer Center

Search for other papers by Nathan Paul Fairman in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Josephine Feliciano Johns Hopkins Kimmel Cancer Center

Search for other papers by Josephine Feliciano in
Current site
Google Scholar
PubMed Close
 MD
,
Tessa Faye Flores Roswell Park Comprehensive Cancer Center

Search for other papers by Tessa Faye Flores in
Current site
Google Scholar
PubMed Close
 MD
,
Debra L. Friedman Vanderbilt-Ingram Cancer Center

Search for other papers by Debra L. Friedman in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Nicolette Gabel University of Michigan Rogel Cancer Center

Search for other papers by Nicolette Gabel in
Current site
Google Scholar
PubMed Close
 PhD, ABPP
,
Christine Hill-Kayser Abramson Cancer Center at the University of Pennsylvania

Search for other papers by Christine Hill-Kayser in
Current site
Google Scholar
PubMed Close
 MD
,
Divya Koura UC San Diego Moores Cancer Center

Search for other papers by Divya Koura in
Current site
Google Scholar
PubMed Close
 MD
,
Kimberley Lee Moffitt Cancer Center

Search for other papers by Kimberley Lee in
Current site
Google Scholar
PubMed Close
 MD, MHS
,
Nita Lee The UChicago Medicine Comprehensive Cancer Center

Search for other papers by Nita Lee in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Allison L. McDonough Mass General Cancer Center

Search for other papers by Allison L. McDonough in
Current site
Google Scholar
PubMed Close
 MD
,
Michelle Melisko UCSF Helen Diller Family Comprehensive Cancer Center

Search for other papers by Michelle Melisko in
Current site
Google Scholar
PubMed Close
 MD
,
Kathi Mooney Huntsman Cancer Institute at the University of Utah

Search for other papers by Kathi Mooney in
Current site
Google Scholar
PubMed Close
 RN, PhD
,
Halle C.F. Moore Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Search for other papers by Halle C.F. Moore in
Current site
Google Scholar
PubMed Close
 MD
,
Natalie Moryl Memorial Sloan Kettering Cancer Center

Search for other papers by Natalie Moryl in
Current site
Google Scholar
PubMed Close
 MD
,
Heather Neuman University of Wisconsin Carbone Cancer Center

Search for other papers by Heather Neuman in
Current site
Google Scholar
PubMed Close
 MD, MS
,
Linda Overholser University of Colorado Cancer Center

Search for other papers by Linda Overholser in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Chirayu Patel Mass General Cancer Center

Search for other papers by Chirayu Patel in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Lindsay Peterson Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Search for other papers by Lindsay Peterson in
Current site
Google Scholar
PubMed Close
 MD, MSCR
,
William Pirl Dana-Farber/Brigham and Women’s Cancer Center

Search for other papers by William Pirl in
Current site
Google Scholar
PubMed Close
 MD, MPH
,
Andrea Porpiglia Fox Chase Cancer Center

Search for other papers by Andrea Porpiglia in
Current site
Google Scholar
PubMed Close
 MD, MSc
,
Lidia Schapira Stanford Cancer Institute

Search for other papers by Lidia Schapira in
Current site
Google Scholar
PubMed Close
 MD
,
Anna Schwartz Fred & Pamela Buffett Cancer Center

Search for other papers by Anna Schwartz in
Current site
Google Scholar
PubMed Close
 PhD, NP
,
Sophia Smith Duke Cancer Institute

Search for other papers by Sophia Smith in
Current site
Google Scholar
PubMed Close
 PhD, MSW
,
Amye Tevaarwerk Mayo Clinic Comprehensive Cancer Center

Search for other papers by Amye Tevaarwerk in
Current site
Google Scholar
PubMed Close
 MD
,
Diane Von Ah The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Search for other papers by Diane Von Ah in
Current site
Google Scholar
PubMed Close
 PhD, RN
,
Robert Wake The University of Tennessee Health Science Center

Search for other papers by Robert Wake in
Current site
Google Scholar
PubMed Close
 MD
,
Eric Yang UCLA Jonsson Comprehensive Cancer Center

Search for other papers by Eric Yang in
Current site
Google Scholar
PubMed Close
 MD
,
Phyllis Zee Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Search for other papers by Phyllis Zee in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Nicole McMillian National Comprehensive Cancer Network

Search for other papers by Nicole McMillian in
Current site
Google Scholar
PubMed Close
 MS, CHES
, and
Deborah Freedman-Cass National Comprehensive Cancer Network

Search for other papers by Deborah Freedman-Cass in
Current site
Google Scholar
PubMed Close
 PhD
Volume/Issue:
Volume 22: Issue 10
Online Publication Date:
Dec 2024
DOI:
https://doi.org/10.6004/jnccn.2024.0062
Restricted access

The NCCN Guidelines for Survivorship include recommendations for screening, evaluation, and treatment of psychosocial and physical problems resulting from adult-onset cancer and its treatment. They also include recommendations to promote healthy behaviors and immunizations in survivors and provide a framework for care coordination. These NCCN Guidelines Insights summarize the panel’s current recommendations regarding sexual health and fertility.

Provided content development and/or authorship assistance

Tara Sanft, Andrew T. Day, K. Scott Baker, Christine Hill-Kayser, Nita Lee, Mindy Goldman, Kathi Mooney, Halle Moore, Amye Tevaarwerk, Nicole McMillian, and Deborah Freedman-Cass

The full and most current version of these NCCN Guidelines is available at NCCN.org.

NCCN CATEGORIES OF EVIDENCE AND CONSENSUS

Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus (≥50%, but <85% support of the Panel) that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

NCCN CATEGORIES OF PREFERENCE

Preferred intervention: Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.

Other recommended intervention: Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.

Useful in certain circumstances: Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.

NCCN recognizes the importance of clinical trials and encourages participation when applicable and available. Trials should be designed to maximize inclusiveness and broad representative enrollment.

PLEASE NOTE

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment.

The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel’s discussion, including the literature reviewed.

The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their application or use in any way.

  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022;72:409–436.

  • 2.

    Emery J, Butow P, Lai-Kwon J, et al. Management of common clinical problems experienced by survivors of cancer. Lancet 2022;399:1537–1550.

  • 3.

    Ragavan MV, Mora RV, Winder K, et al. Impact of a comprehensive financial resource on financial toxicity in a national, multiethnic sample of adult, adolescent/young adult, and pediatric patients with cancer. JCO Oncol Pract 2023;19:e286–297.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Hodgkinson K, Butow P, Fuchs A, et al. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. Gynecol Oncol 2007;104:381–389.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Hoffman KE, McCarthy EP, Recklitis CJ, Ng AK. Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. Arch Intern Med 2009;169:1274–1281.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Yao G, Lai JS, Garcia SF, et al. Positive and negative psychosocial impacts on cancer survivors. Sci Rep 2023;13:14749.

  • 7.

    Adams E, Boulton MG, Horne A, et al. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol) 2014;26:10–17.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol 2014;15:223–231.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Kreissl S, Mueller H, Goergen H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin’s lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol 2016;17:1453–1462.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Meretoja TJ, Leidenius MH, Tasmuth T, et al. Pain at 12 months after surgery for breast cancer. JAMA 2014;311:90–92.

  • 11.

    Palmer C. Cognition and cancer treatment. Monitor on Psychology 2020;51:42.

  • 12.

    Beckjord EB, Reynolds KA, van Londen GJ, et al. Population-level trends in posttreatment cancer survivors’ concerns and associated receipt of care: results from the 2006 and 2010 LIVESTRONG surveys. J Psychosoc Oncol 2014;32:125–151.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Ribeiro Pereira ACP, Koifman RJ, Bergmann A. Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up. Breast 2017;36:67–73.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Hayes SC, Janda M, Ward LC, et al. Lymphedema following gynecological cancer: results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecol Oncol 2017;146:623–629.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Guedes TSR, Guedes MBOG, Santana RC, et al. Sexual dysfunction in women with cancer: a systematic review of longitudinal studies. Int J Environ Res Public Health 2022;19:11921.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018;36:1994–2001.

  • 17.

    Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436–445.

  • 18.

    Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. Cancer Control 2010;17:44–51.

  • 19.

    Ellis R, Smith A, Wilson S, et al. The prevalence of erectile dysfunction in post-treatment colorectal cancer patients and their interests in seeking treatment: a cross-sectional survey in the west-midlands. J Sex Med 2010;7:1488–1496.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Bernal J, Venkatesan K, Martins FE. Erectile dysfunction in pelvic cancer survivors and current management options. J Clin Med 2023;12:2697.

  • 21.

    Hendren SK, O’Connor BI, Liu M, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005;242:212–223.

  • 22.

    Chang CP, Wilson CM, Rowe K, et al. Sexual dysfunction among gynecologic cancer survivors in a population-based cohort study. Support Care Cancer 2022;31:51.

  • 23.

    Chang CP, Ho TF, Snyder J, et al. Breast cancer survivorship and sexual dysfunction: a population-based cohort study. Breast Cancer Res Treat 2023;200:103–113.

  • 24.

    Rhoten BA. Head and neck cancer and sexuality: a review of the literature. Cancer Nurs 2016;39:313–320.

  • 25.

    Low C, Fullarton M, Parkinson E, et al. Issues of intimacy and sexual dysfunction following major head and neck cancer treatment. Oral Oncol 2009;45:898–903.

  • 26.

    Mejia-Gomez J, Petrovic I, Doherty M, et al. Sexual dysfunction in female patients with anal cancer treated with curative intent: a systematic review of the literature. Radiother Oncol 2023;178:109437.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Den Oudsten BL, Traa MJ, Thong MS, et al. Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. Eur J Cancer 2012;48:3161–3170.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Wheldon CW, Polter EJ, Rosser BRS, et al. Pain and loss of pleasure in receptive anal sex for gay and bisexual men following prostate cancer treatment: results from the Restore-1 study. J Sex Res 2022;59:826–833.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Dickstein DR, Edwards CR, Rowan CR, et al. Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus. Nat Rev Gastroenterol Hepatol 2024;21:377–405.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Thompson LMA, Donovan KA. Discussions about sexual health: an unmet need among patients with human papillomavirus-related oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2021;110:394–395.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Sfeir M, Haidar S, Khoury NE, et al. Profiles of university students in terms of sexual dysfunction: the role of anxiety, depression, eating attitudes, and mindfulness. Prim Care Companion CNS Disord 2024;26:23m03682.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Saadedine M, Faubion S, Kingsberg S, et al. Adverse childhood experiences and sexual dysfunction in midlife women: is there a link? J Sex Med 2023;20:792–799.

  • 33.

    Bober SL, Varela VS. Sexuality in adult cancer survivors: challenges and intervention. J Clin Oncol 2012;30:3712–3719.

  • 34.

    Jackson SE, Wardle J, Steptoe A, Fisher A. Sexuality after a cancer diagnosis: a population-based study. Cancer 2016;122:3883–3891.

  • 35.

    Bober SL, Carter J, Falk S. Addressing female sexual function after cancer by internists and primary care providers. J Sex Med 2013;10(Suppl 1):112–119.

  • 36.

    Reese JB, Sorice K, Beach MC, et al. Patient-provider communication about sexual concerns in cancer: a systematic review. J Cancer Surviv 2017;11:175–188.

  • 37.

    Sporn NJ, Smith KB, Pirl WF, et al. Sexual health communication between cancer survivors and providers: how frequently does it occur and which providers are preferred? Psychooncology 2015;24:1167–1173.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    White ID, Allan H, Faithfull S. Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy? Br J Cancer 2011;105:903–910.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Pratt-Chapman ML, Alpert AB, Castillo DA. Health outcomes of sexual and gender minorities after cancer: a systematic review. Syst Rev 2021;10:183.

  • 40.

    Dickstein DR, Edwards CR, Lehrer EJ, et al. Sexual health and treatment-related sexual dysfunction in sexual and gender minorities with prostate cancer. Nat Rev Urol 2023;20:332–355.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 119: Female sexual dysfunction. Obstet Gynecol 2011;117:996–1007.

  • 42.

    Gilbert E, Ussher JM, Perz J. Sexuality after breast cancer: a review. Maturitas 2010;66:397–407.

  • 43.

    Krychman M, Millheiser LS. Sexual health issues in women with cancer. J Sex Med 2013;10(Suppl 1):5–15.

  • 44.

    Morreale MK. The impact of cancer on sexual function. Adv Psychosom Med 2011;31:72–82.

  • 45.

    Rodrigues AC, Teixeira R, Teixeira T, et al. Impact of pelvic radiotherapy on female sexuality. Arch Gynecol Obstet 2012;285:505–514.

  • 46.

    Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428–7436.

  • 47.

    Ganz PA, Desmond KA, Belin TR, et al. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999;17:2371–2380.

  • 48.

    Lammerink EA, de Bock GH, Pras E, et al. Sexual functioning of cervical cancer survivors: a review with a female perspective. Maturitas 2012;72:296–304.

  • 49.

    Fobair P, Stewart SL, Chang S, et al. Body image and sexual problems in young women with breast cancer. Psychooncology 2006;15:579–594.

  • 50.

    Reed SD, Guthrie KA, Newton KM, et al. Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. Am J Obstet Gynecol 2014;210:244.e1–11.

  • 51.

    Brotto LA, Erskine Y, Carey M, et al. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012;125:320–325.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Hummel SB, van Lankveld J, Oldenburg HSA, et al. Efficacy of internet-based cognitive behavioral therapy in improving sexual functioning of breast cancer survivors: results of a randomized controlled trial. J Clin Oncol 2017;35:1328–1340.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Hickey M, Marino JL, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 2016;158:79–90.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Sutton KS, Boyer SC, Goldfinger C, et al. To lube or not to lube: experiences and perceptions of lubricant use in women with and without dyspareunia. J Sex Med 2012;9:240–250.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015;33:3394–3400.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Yang EJ, Lim JY, Rah UW, Kim YB. Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: a randomized controlled trial. Gynecol Oncol 2012;125:705–711.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2014;2014:CD007291.

  • 58.

    Fooladi E, Davis SR. An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother 2012;13:2131–2142.

  • 59.

    Krychman ML. Vaginal estrogens for the treatment of dyspareunia. J Sex Med 2011;8:666–674.

  • 60.

    Raghunandan C, Agrawal S, Dubey P, et al. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7:1284–1290.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2017;3:313–319.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol 2024;10:103–108.

  • 63.

    Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 2015;22:950–963.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Archer DF, Labrie F, Montesino M, Martel C. Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 mug estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol 2017;174:1–8.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282–288.

  • 66.

    Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23:243–256.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Labrie F, Archer DF, Bouchard C, et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open- label study. Maturitas 2015;81:46–56.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Scheffers CS, Armstrong S, Cantineau AE, et al. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev 2015;1:CD011066.

  • 69.

    Barton DL, Sloan JA, Shuster LT, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 2018;26:643–650.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Barton DL, Shuster LT, Dockter T, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer 2018;26:1335–1343.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Bachmann GA, Komi JO Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17:480–486.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014;17:173–182.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20:623–630.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    De Rosa N, Lavitola G, Giampaolino P, et al. Impact of ospemifene on quality of life and sexual function in young survivors of cervical cancer: a prospective study. Biomed Res Int 2017;2017:7513610.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Jaspers L, Feys F, Bramer WM, et al. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 2016;176:453–462.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Gao Z, Yang D, Yu L, Cui Y. Efficacy and safety of flibanserin in women with hypoactive sexual desire disorder: a systematic review and meta-analysis. J Sex Med 2015;12:2095–2104.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Goldfarb SB, Carter J, Arkema A, et al. Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy. J Clin Oncol 2023;41(Suppl 16):Abstract 12015.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Portman DJ, Brown L, Yuan J, et al. Flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the PLUMERIA study. J Sex Med 2017;14:834–842.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014;21:633–640.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899–908.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc 2017;92:114–128.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Segraves RT, Croft H, Kavoussi R, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001;27:303–316.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Segraves RT, Clayton A, Croft H, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. J Clin Psychopharmacol 2004;24:339–342.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Landén M, Eriksson E, Agren H, Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999;19:268–271.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Cavalcanti AL, Bagnoli VR, Fonseca AM, et al. Effect of sildenafil on clitoral blood flow and sexual response in postmenopausal women with orgasmic dysfunction. Int J Gynaecol Obstet 2008;102:115–119.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Yang CC, Cao YY, Guan QY, et al. Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating drug response. Int J Impot Res 2008;20:105–110.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Alexander MS, Rosen RC, Steinberg S, et al. Sildenafil in women with sexual arousal disorder following spinal cord injury. Spinal Cord 2011;49:273–279.

  • 88.

    Basson R, McInnes R, Smith MD, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11:367–377.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003;110:1014–1024.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Berman JR, Berman LA, Toler SM, et al. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003;170:2333–2338.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001;108:623–628.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Caruso S, Rugolo S, Agnello C, et al. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006;85:1496–1501.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    van Rooij K, Poels S, Worst P, et al. Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin (1A) receptor agonist in women with SSRI-induced sexual dysfunction. A preliminary study. Eur J Pharmacol 2015;753:246–251.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Gunter J. Genitourinary syndrome of menopause and the false promise of vaginal laser therapy. JAMA Netw Open 2023;6:e2255706.

  • 95.

    Lami A, Alvisi S, Baldassarre M, et al. Safety and efficacy of non-ablative CO2 laser treatment of vulvo-vaginal atrophy in women with history of breast cancer. Arch Gynecol Obstet 2024;309:1575–1583.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Hersant B, Werkoff G, Sawan D, et al. Carbon dioxide laser treatment for vulvovaginal atrophy in women treated for breast cancer: preliminary results of the feasibility EPIONE trial. Ann Chir Plast Esthet 2020;65:e23–31.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Pearson A, Booker A, Tio M, Marx G. Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study. Breast Cancer Res Treat 2019;178:135–140.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    D’Oria O, Giannini A, Buzzaccarini G, et al. Fractional Co2 laser for vulvo-vaginal atrophy in gynecologic cancer patients: a valid therapeutic choice? A systematic review. Eur J Obstet Gynecol Reprod Biol 2022;277:84–89.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Faw CA, Brannigan RE. Hypogonadism and cancer survivorship. Curr Opin Endocrinol Diabetes Obes 2020;27:411–418.

  • 100.

    Cooper K, Martyn-St James M, Kaltenthaler E, et al. Interventions to treat premature ejaculation: a systematic review short report. Health Technol Assess 2015;19:1–180, v-vi.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Giuliano F, Clement P. Pharmacology for the treatment of premature ejaculation. Pharmacol Rev 2012;64:621–644.

  • 102.

    Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998;159:425–427.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol 2004;46:510–515.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Fink HA, Mac Donald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002;162:1349–1360.

  • 105.

    Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc 2009;84:139–148.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Hubanks JM, Umbreit EC, Karnes RJ, Myers RP. Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. Eur Urol 2012;61:878–884.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Yang L, Qian S, Liu L, et al. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis. Urol Int 2013;90:339–347.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline. J Clin Oncol 2018;36:492–511.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003;42:1855–1860.

  • 110.

    Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999;83:21C–28C.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    American Urological Association. Management of erectile dysfunction. Accessed June 5, 2020. Available at: https://www.auanet.org/guidelines/male-sexual-dysfunction-erectile-dysfunction

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Zhao C, Kim SW, Yang DY, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:380–387.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Rajfer J, Aliotta PJ, Steidle CP, et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo- controlled study in the US. Int J Impot Res 2007;19:95–103.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:351–359.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Shim YS, Pae CU, Cho KJ, et al. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. Int J Impot Res 2014;26:76–80.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med 2016;374:611–624.

  • 118.

    Cunningham GR, Stephens-Shields AJ, Rosen RC, et al. Testosterone treatment and sexual function in older men with low testosterone levels. J Clin Endocrinol Metab 2016;101:3096–3104.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284–293.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Corona G, Vignozzi L, Sforza A, Maggi M. Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 2013;31:103–125.

  • 121.

    Khera M, Bhattacharya RK, Blick G, et al. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med 2011;8:3204–3213.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Rosenthal BD, May NR, Metro MJ, et al. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006;67:571–574.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Hwang TI, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006;18:400–404.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10:579–588.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Fusco F, Verze P, Capece M, Napolitano L. Suppression of spermatogenesis by exogenous testosterone. Curr Pharm Des 2021;27:2750–2753.

  • 126.

    Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004;291:2978–2984.

  • 127.

    Lamina S, Okoye CG, Dagogo TT. Therapeutic effect of an interval exercise training program in the management of erectile dysfunction in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:125–129.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Khoo J, Piantadosi C, Duncan R, et al. Comparing effects of a low- energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med 2011;8:2868–2875.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Khoo J, Piantadosi C, Worthley S, Wittert GA. Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes (Lond) 2010;34:1396–1403.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med 2010;7:2201–2208.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Andersson E, Walen C, Hallberg J, et al. A randomized controlled trial of guided Internet-delivered cognitive behavioral therapy for erectile dysfunction. J Sex Med 2011;8:2800–2809.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Aubin S, Heiman JR, Berger RE, et al. Comparing sildenafil alone vs. sildenafil plus brief couple sex therapy on erectile dysfunction and couples’ sexual and marital quality of life: a pilot study. J Sex Marital Ther 2009;35:122–143.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Banner LL, Anderson RU. Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. J Sex Med 2007;4:1117–1125.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Boddi V, Castellini G, Casale H, et al. An integrated approach with vardenafil orodispersible tablet and cognitive behavioral sex therapy for treatment of erectile dysfunction: a randomized controlled pilot study. Andrology 2015;3:909–918.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Wylie KR. Treatment outcome of brief couple therapy in psychogenic male erectile disorder. Arch Sex Behav 1997;26:527–545.

  • 136.

    Canada AL, Neese LE, Sui D, Schover LR. Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer 2005;104:2689–2700.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Schover LR, Canada AL, Yuan Y, et al. A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer 2012;118:500–509.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Geraerts I, Van Poppel H, Devoogdt N, et al. Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: a randomized controlled trial. Int J Impot Res 2016;28:9–13.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Prota C, Gomes CM, Ribeiro LH, et al. Early postoperative pelvic-floor biofeedback improves erectile function in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. Int J Impot Res 2012;24:174–178.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Nelson CJ, Ahmed A, Valenzuela R, et al. Assessment of penile vibratory stimulation as a management strategy in men with secondary retarded orgasm. Urology 2007;69:552–555; discussion 555–556.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Hollander AB, Pastuszak AW, Hsieh TC, et al. Cabergoline in the treatment of male orgasmic disorder–a retrospective pilot analysis. Sex Med 2016;4:e28–33.

  • 142.

    Liu JL, Chu KY, Gabrielson AT, et al. Restorative therapies for erectile dysfunction: position statement from the Sexual Medicine Society of North America (SMSNA). Sex Med 2021;9:100343.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Kort JD, Eisenberg ML, Millheiser LS, Westphal LM. Fertility issues in cancer survivorship. CA Cancer J Clin 2014;64:118–134.

  • 144.

    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718–1729.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood 2008;111:101–108.

  • 146.

    Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–2370.

  • 147.

    Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012;104:386–405.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Quinn MM, Letourneau JM, Rosen MP. Contraception after cancer treatment: describing methods, counseling, and unintended pregnancy risk. Contraception 2014;89:466–471.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Polland A, Berookhim BM. Fertility concerns in men with genitourinary malignancies: treatment dilemmas, fertility options, and medicolegal considerations. Urol Oncol 2016;34:399–406.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Vakalopoulos I, Dimou P, Anagnostou I, Zeginiadou T. Impact of cancer and cancer treatment on male fertility. Hormones (Athens) 2015;14:579–589.

  • 151.

    Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004;100:732–737.

  • 152.

    Bimbatti D, Lai E, Pierantoni F, et al. Patient reported outcomes, paternity, relationship, and fertility in testicular cancer survivors: results from a prospective observational single institution trial. Patient Prefer Adherence 2022;16:3393–3403.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2019;112:1022–1033.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    Ahmed Y, Khan AMH, Rao UJ, et al. Fertility preservation is an imperative goal in the clinical practice of radiation oncology: a narrative review. Ecancermedicalscience 2022;16:1461.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 155.

    Fernbach A, Lockart B, Armus CL, et al. Evidence-based recommendations for fertility preservation options for inclusion in treatment protocols for pediatric and adolescent patients diagnosed with cancer. J Pediatr Oncol Nurs 2014;31:211–222.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Nass SJ, Beaupin LK, Demark-Wahnefried W, et al. Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop. Oncologist 2015;20:186–195.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    Waks AG, Partridge AH. Fertility preservation in patients with breast cancer: necessity, methods, and safety. J Natl Compr Canc Netw 2016;14:355–363.

  • 158.

    Koh B, Tan DJH, Ng CH, et al. Patterns in cancer incidence among people younger than 50 years in the US, 2010 to 2019. JAMA Netw Open 2023;6:e2328171.

  • 159.

    Dorfman CS, Stalls JM, Mills C, et al. Addressing barriers to fertility preservation for cancer patients: the role of oncofertility patient navigation. J Oncol Navig Surviv 2021;12:332–348.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 160.

    Sena LA, Sedhom R, Scott S, et al. Trainee-led quality improvement project to improve fertility preservation counseling for patients with cancer. JCO Oncol Pract 2022;18:e403–411.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Patel P, Kohn TP, Cohen J, et al. Evaluation of reported fertility preservation counseling before chemotherapy using the quality oncology practice initiative survey. JAMA Netw Open 2020;3:e2010806.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Murphy D, Orgel E, Termuhlen A, et al. Why healthcare providers should focus on the fertility of AYA cancer survivors: it’s not too late! Front Oncol 2013;3:248.

  • 163.

    Chen H, Xiao L, Li J, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2019;3:CD008018.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Armuand GM, Wettergren L, Rodriguez-Wallberg KA, Lampic C. Desire for children, difficulties achieving a pregnancy, and infertility distress 3 to 7 years after cancer diagnosis. Support Care Cancer 2014;22:2805–2812.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Lambertini M, Blondeaux E, Bruzzone M, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol 2021;39:3293–3305.

  • 166.

    Meistrich ML. Risks of genetic damage in offspring conceived using spermatozoa produced during chemotherapy or radiotherapy. Andrology 2020;8:545–558.

  • 167.

    Choy JT, Brannigan RE. The determination of reproductive safety in men during and after cancer treatment. Fertil Steril 2013;100:1187–1191.

Copyright:
Copyright © 2024 by the National Comprehensive Cancer Network 2024
Page Numbers:
11
Article Category:
Research Article
Print Publication Date:
01 Dec 2024
Online Publication Date:
Dec 2024

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 8589 8589 781
PDF Downloads 1813 1813 149
EPUB Downloads 0 0 0